Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST.
A live webcast will be available in the Investors section of Cardiol’s website: www.cardiolrx.com/investors/events-presentations/.